Winnergy Medical Public Company Limited

Winner Medical Public Company Limited, or WINMED, reported second quarter 2026 results with total revenue of 209.22 million baht, up 39% from the same period last year, and net profit of 6.40 million baht, up 237% from net profit of 1.90 million baht a year earlier. Growth was driven by the medical blood recruitment products and services business, including Pathogen Inactivation, or PI, technology, which is now used by more than 45 hospitals. The company is also expanding into the cell and gene therapy market by delivering CliniMACS Prodigy and MACSQuant Analyzer instruments to government agencies to support CAR-T Cell treatment and generate recurring revenue from related reagents and products.

Three Thai listed companies reported strong second-half results. WINMED posted second-quarter 2026 profit of 6.40 million baht, up 237%, with total revenue of 209.22 million baht, driven by growth in blood recruitment products and services and cell and molecular technology products. Management said the second-half outlook is bright after its Pathogen Inactivation innovation was well received by public and private hospitals, and it is moving ahead with launching Thailand's first mobile platelet donation bus. IROYAL reported first-half 2026 total revenue of 232.73 million baht and net profit of 65.91 million baht, up 34%, with a backlog of 620 million baht and projects ready for bidding in 2026 to 2027 worth more than 2.5 billion baht. The board approved an interim dividend of 0.1304 baht per share. SCAP posted record profit in the second quarter of 2026, with total revenue of 1.45555 billion baht and net profit of 477.35 million baht, up 155.05% from the same period last year, driven by motorcycle hire-purchase lending and mobile phone hire-purchase lending through the Locked Phone system, along with effective control of debt quality and expenses.

Winner Medical Public Company Limited, or WINMED, presented the INTERCEPT™ Blood System at the Hospital Blood Bank 2026 academic conference to enhance blood safety before it is used to treat patients. This pathogen inactivation technology can directly inhibit and destroy pathogens in blood components, reducing the risk of transfusion-transmitted infections and aligning with the public health trend that emphasizes proactive risk prevention. Having an internationally recognized product strengthens WINMED's competitive edge as a provider of high-value-added medical solutions, particularly in the blood service medicine segment, which has high barriers to market entry. Participation in this event also reflects the company's role in driving innovation into the country's blood service system and building collaborative networks with medical professionals.

Winner Medical, or WINMED, presented innovations and technologies in transfusion medicine at the Hospital Blood Bank 2026 academic conference. A highlight was a special lecture by Associate Professor Wing Commander Dr. Parichart Permpikul on the application of Pathogen Inactivation technology to enhance the safety of blood components. WINMED provides the INTERCEPT Blood System, which can inactivate and destroy pathogens in platelets before they are used to treat patients, helping to reduce the risk of transfusion-transmitted infections and elevate the standards of Thai blood banks to international levels. The event was held at the S.D. Avenue Hotel in Bangkok.